George Frangeskides, Exec-Chair at Alba Mineral Resources, discusses grades at the Clogau Gold Mine. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.25
Bid: 6.20
Ask: 6.50
Change: -0.65 (-9.29%)
Spread: 0.30 (4.839%)
Open: 7.00
High: 7.00
Low: 6.35
Prev. Close: 7.00
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further re Paraytec Limited

5 Aug 2020 07:00

RNS Number : 1386V
Braveheart Investment Group plc
05 August 2020
 

RNS Reach announcement (non-regulatory)

5 August 2020

 

 

Braveheart Investment Group plc

("Braveheart" or the "Group")

Further re Paraytec Limited

Further to the announcement made on 7 July 2020, Braveheart is pleased to provide an update concerning the development of a COVID-19 test that Paraytec Limited is conducting with the University of Sheffield.

WP1 Construction of a viral mimic

Braveheart previously reported on the successful production of the viral SPIKE protein. It can now report that sub-micron-sized polystyrene microspheres have been produced to which multiple copies of the SPIKE protein have been successfully bonded, generating a viral mimic that is the same size as the COVID-19 coronavirus, thus completing this workpackage.

WP2 Development of CAPTURE system

 

The CAPTURE module comprises a system in which a specialised surface is coated with a macromolecule that binds the virus very tightly. Here the virus-binding molecule undergoing analysis is COVID-19 DNA aptamer that has been supplied to Paraytec. The biotin-binding protein avidin has been bonded to the Capture module, which is composed of 10 micron microspheres, and the resultant surface coated with a biotinylated derivative of the aptamer, completing this workpackage.

 

WP3 Development of the Signal Generation Module

 

Construction of Signal Generation components has begun. The Signal Generation module consists of fluorescent-nanospheres derivatised with a synthetic COVID-19 virus binding protein that associates with trapped virus particles within 5 minutes. The DNA coding for the synthetic protein has been generated and has been introduced into cells growing in culture, to enable the protein to be purified and subsequently coated onto the nanospheres. Purified protein has been obtained and work has been initiated to ensure the protein will be correctly oriented when attached to nanospheres, to maximise the rate of association with viral particles, and thus the speed at which a test result can be generated.

 

Over the next month, it is expected that the construction of the Signal Generation module will be completed, which will lead the way to establishing proof-of-concept by early October.

 

Professor Carl Smythe commented "We continue to make progress in the development of this novel approach to testing for Coronavirus. A key requirement is the ability to deliver a test result with very fast turnaround. The current gold standard uses PCR which involves repeated rounds of enzyme-catalysed production of DNA corresponding to known viral genes, a process that takes several hours, and requires access to highly specialised lab equipment. Other approaches have begun to be rolled out (see https://www.gov.uk/government/news/roll-out-of-2-new-rapid-coronavirus-tests-ahead-of-winter). These, while avoiding specialised equipment, nonetheless also target viral genes, generating a positive signal via an enzyme-catalysed reaction, which takes 1.5 hours. This of necessity reduces the number of tests that can be performed in any one day. Our approach, in which viral attachment to affinity macromolecules may be imaged directly using a highly sensitive detection system, has the potential both to undertake many tests in parallel, as well as delivering results in minutes, all without the need for trained health professionals for their operation.

 

 

For further information

Braveheart Investment Group plcTrevor Brown, Chief Executive Officer

Tel: 01738 587555

 

 

About RNS Reach announcements

 

This is an RNS Reach announcement. RNS Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on RNS Reach.

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
NRAFZGGRNDDGGZM
Date   Source Headline
27th Mar 202412:03 pmRNSHolding(s) in Company
6th Mar 20247:00 amRNSAcquisition of further interest in Autins Group
4th Mar 202411:48 amRNSInvestment update – Paraytec Limited
4th Mar 20247:00 amRNSCompletion of sale of Phasefocus
9th Jan 202412:00 pmRNSHolding(s) in Company
22nd Dec 20231:30 pmRNSHolding(s) in Company
22nd Dec 20237:00 amRNSPortfolio update - Proposed sale of Phasefocus
15th Dec 202311:41 amRNSInvestment update - Paraytec Limited
15th Dec 202310:16 amRNSReplacement: Half-year Report
14th Dec 20237:00 amRNSHalf-year Report
29th Nov 20237:00 amRNSInvestment update - Paraytec Limited
14th Nov 20239:02 amRNSHolding(s) in Company
17th Oct 20237:00 amRNSInvestment update – Paraytec Limited
10th Oct 202311:15 amRNSHolding(s) in Company
8th Sep 20237:00 amRNSInvestment update – Kirkstall Limited
8th Sep 20237:00 amRNSBlock admission six monthly return
21st Aug 20237:00 amRNSFurther investment in Phasefocus Holdings Limited
28th Jul 20232:25 pmRNSInvestment update on Paraytec Limited
28th Jul 202311:54 amRNSResult of AGM
5th Jul 20237:00 amRNSPosting of annual report and notice of AGM
4th Jul 20237:00 amRNSHolding(s) in Company
3rd Jul 20237:00 amRNSFinal Results for the year ended 31 March 2023
31st May 20237:00 amRNSInvestment update – Phasefocus Holdings Limited
3rd May 20237:00 amRNSUpdate on investments
24th Apr 202310:49 amRNSHolding(s) in Company
27th Mar 20237:00 amRNSGrant of options
13th Mar 20239:34 amRNSHolding(s) in Company
9th Mar 20237:00 amRNSBlock admission six monthly return
10th Feb 20231:26 pmRNSHolding(s) in Company
30th Jan 20234:37 pmRNSHolding(s) in Company
16th Jan 20237:00 amRNSDirector/PDMR Shareholding
10th Jan 20237:00 amRNSOperational update
22nd Dec 20229:14 amRNSHolding(s) in Company
19th Dec 20229:25 amRNSDirector/PDMR Shareholding
19th Dec 20229:11 amRNSAcquisition of interest in Image Scan Holdings plc
13th Dec 20224:37 pmRNSHolding(s) in Company
15th Nov 20223:09 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirector/PDMR Shareholding
28th Oct 20227:00 amRNSHalf-year Report
21st Oct 202210:33 amRNSHolding(s) in Company
20th Oct 20221:59 pmRNSAcquisition of further interest in Autins
5th Oct 20223:15 pmRNSHolding(s) in Company
5th Oct 202212:28 pmRNSAcquisition of further interest in Aukett Swanke
30th Sep 20225:00 pmRNSTotal Voting Rights
20th Sep 20227:00 amRNSPlacing and subscription to raise £750,000
9th Sep 20227:00 amRNSBlock admission six monthly return
6th Sep 20227:00 amRNSHolding(s) in Company
2nd Sep 202211:20 amRNSHolding(s) in Company
1st Sep 20227:00 amRNSAcquisition of further interest in Aukett Swanke
31st Aug 20225:00 pmRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.